Denileukin Diftitox as Novel Targeted Therapy for Lymphoid Malignancies

Author： Wong Bryan Gregory Stephanie Dang Nam

ISSN： 0735-7907

Source： Cancer Investigation, Vol.25, Iss.6, 2007-09, pp. : 495-501

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimizing denileukin diftitox (Ontak^®®) therapy

By Duvic Madeleine Talpur Rakhshandra

Future Oncology, Vol. 4, Iss. 4, 2008-08 ,pp. : 457-469

Future Medicine

Access to resources Recommend Favorite

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study

By Foss Francine M.

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1373-1379

Informa Healthcare

Access to resources Recommend Favorite

Current status of molecular targeted therapy for hematologic malignancies: introduction

By Ueda Takanori

International Journal of Clinical Oncology, Vol. 19, Iss. 1, 2014-02 ,pp. : 1-2

Springer Publishing Company

Access to resources Recommend Favorite

Local Treatment for Lymphoid Malignancies of the Eye

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 10, 2009-12 ,pp. : 1123-1128

Bentham Science Publishers

Access to resources Recommend Favorite

Pentostatin and purine analogs for indolent lymphoid malignancies

By Ho Anthony D Hensel Manfred

Future Oncology, Vol. 2, Iss. 2, 2006-04 ,pp. : 169-183

Future Medicine

Access to resources Recommend Favorite